Company intelligence / Profile preview

Braintrust

Atlanta, Georgia, USAusebraintrust.com ↗

Ownership: Private
Development stage: Commercial

Overview

Brain Trust Bio has received approval to commence Phase I clinical trials in Australia for its proprietary continuous intrathecal drug delivery platform targeting ALS and other CNS diseases. Early compassionate use cases have shown over two years of treatment without observed side effects, suggesting potential to extend life expectancy and improve quality of life. The Australian trial is designed to be equivalent to U.S. standards, allowing direct progression to Phase II trials stateside if successful

Therapeutic areas: Neurology
Modalities: Small molecule (specifically IT-Riluzole)Drug delivery device (Continuous Intrathecal Drug Delivery Method)
Industry: Biotech

Partnerships

Flinders UniversitySunshine Coast Hospital

Beyond the preview

Go deeper on Braintrust.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Braintrust.

Explore the full profile